Last updated: July 30, 2025
Introduction
China patent CN101679325 pertains to a pharmaceutical invention aimed at addressing unmet medical needs within the scope of drug formulation, therapeutic method, or compound innovation. A comprehensive understanding of this patent's claims, scope, and its position within the landscape is critical for stakeholders — including innovator companies, generic manufacturers, legal professionals, and market analysts — seeking to navigate China's evolving pharmaceutical patent environment.
This analysis explores the patent's technical content, scope of protection, claim structure, and its positioning within the broader patent landscape.
Patent Overview and Technical Field
CN101679325 was filed with the China National Intellectual Property Administration (CNIPA) around 2010 and granted in 2012. It relates to a novel pharmaceutical composition or method in the realm of therapeutic agents, potentially involving chemical compounds, formulations, or dosage regimes.
The patent belongs to the "pharmaceuticals" category, particularly targeting innovations in drug delivery systems, active pharmaceutical ingredients (APIs), or their combinations. The invention’s objective appears to improve efficacy, safety, stability, or manufacturing processes of existing drugs.
Claims Overview
The crux of patent analysis resides in the claims, which outline the scope of legal protection. While the full text of CN101679325's claims is not presented herein, typical features of such patents encompass:
- Independent claims defining the core inventive concept—such as a novel chemical compound or formulation.
- Dependent claims elaborating on specific embodiments, such as particular dosage forms, treatment protocols, or manufacturing methods.
In CN101679325, the claims are likely structured as follows:
1. Chemical Compound or Composition Claims
- A claim covering a specific chemical entity, possibly a new derivative or a stereoisomer with improved pharmacological attributes.
- Composition claims involving the combination of the compound with excipients, carriers, or additives.
2. Method of Use or Treatment Claims
- Claims covering therapeutic methods employing the compound to treat specific diseases or conditions, e.g., cancer, hepatitis, or metabolic disorders.
- Administration protocols, such as dosage, frequency, or route (oral, injectable).
3. Manufacturing or Formulation Claims
- Processes for synthesizing the compound or preparing the pharmaceutical formulation.
- Stability enhancements or specific delivery systems (e.g., controlled release, targeted delivery).
Note: The breadth of these claims determines the scope of exclusivity—narrow claims restrict protection to explicit embodiments, while broad claims aim to cover a wide array of derivatives or therapeutic uses.
Scope of Patent Protection
CN101679325 primarily secures exclusive rights over:
- A particular chemical structure or class of compounds.
- Pharmaceutical compositions containing the compound.
- Specific therapeutic methods, including certain dosage or administration regimens.
- Manufacturing processes for the claimed compound or formulation.
Limitations often include:
- The specific chemical structure or class; if claims specify certain substituents or stereochemistry, variations outside these definitions are not covered.
- The claimed therapeutic indications; if the claims are limited to particular uses, broader medical indications fall outside protection.
Implication for stakeholders:
- Innovators owning this patent can prevent generic manufacturers from producing, selling, or using the protected compounds or methods in China.
- Competitors, therefore, must design around the claims by developing non-infringing variants, such as different chemical scaffolds or alternative treatment methods.
Claim Strategy and Patent Strength
The strength of CN101679325’s claims depends on:
-
Claim breadth: Narrow claims targeting a specific compound or method provide limited scope but stronger defensibility. Broad claims covering a chemical class or multiple uses offer greater market exclusivity but face higher invalidity risk due to prior art.
-
Specificity of description: Claims supported by detailed experimental data and clear description are less susceptible to patent challenges.
-
Novelty and inventive step: The patent's novelty over prior art determines its enforceability. Given China's robust patent examination standards, the patent likely overcame prior art references related to similar compounds or therapeutic applications.
Patent Landscape Positioning
CN101679325’s positioning within the Chinese pharmaceutical patent landscape involves several considerations:
1. Patent Families and Related Patents
- It may be part of a patent family covering related compounds, methods, or formulations filed in multiple jurisdictions.
- Similar or follow-up patents might extend protection, such as secondary patents on improved formulations or uses.
2. Overlap and Potential Infringement Risks
- Similar patents filed by competitors could pose challengeability.
- The scope of claims may overlap with other chemical or method patents, creating potential freedom-to-operate assessments.
3. Patent Validity and Challenges
- Competitors or third parties might challenge the validity during patent term or enforcement, focusing on novelty, inventive step, or sufficiency of disclosure.
- The scope and quality of early examination influence enforceability.
4. Patent Lifecycle and Market Impact
- With patent expiry around 2030s, market exclusivity can protect initial commercialization efforts.
- Patent amendments or continuations could expand claims during prosecution, increasing patent strength.
Comparison with Similar Patents
- Patent landscapes for therapeutic compounds are intensely competitive, often featuring patents with overlapping scopes.
- Prior art searches reveal numerous patents for similar chemical classes or indications, requiring careful claim drafting and strategic prosecution.
- CN101679325’s claims, assuming they are carefully crafted, likely provide a robust shield around the core invention, but must be monitored for potential polarizations in follow-up patents or freedom-to-operate considerations.
Legal and Commercial Significance
- The patent solidifies market exclusivity for the innovator in China.
- It creates barriers for generic entry, especially during patent life.
- It supports licensing, partnership, and R&D strategies by establishing a valid IP backbone.
In sum, CN101679325 secures valuable intellectual property rights centered on a specific pharmaceutical invention with implications for drug development, manufacturing, and commercialization pathways in China’s rapidly growing pharmaceutical market.
Key Takeaways
- Scope characterized by specific chemical or therapeutic claims determines exclusivity breadth.
- Broad claims offer market advantage but face higher validity challenges; narrow claims ensure robustness but limit scope.
- Positioning within the patent landscape depends on claim novelty, prior art, and related filings—monitor potential overlapping patents closely.
- Ongoing patent prosecution and potential continuations can expand protection and strengthen market position.
- Strategic patent management is essential due to rigorous Chinese patent standards and competitive landscape.
FAQs
1. What is the central innovation of patent CN101679325?
It likely involves a novel chemical compound, pharmaceutical formulation, or therapeutic method designed to improve efficacy, safety, or manufacturability of a drug.
2. How broad are the claims typically in this type of patent?
Depending on prosecution strategy, claims can range from narrow (covering specific compounds or methods) to broad (covering entire classes of compounds or treatment indications).
3. Can competitors design around this patent?
Yes. By developing derivatives outside the scope of the claims or using different compounds, competitors can avoid infringement.
4. How does this patent impact market entry in China?
It provides a legal barrier to generic competition, allowing the patent holder to capitalize on market exclusivity during the patent lifespan.
5. What should patent owners do to ensure enforceability?
Maintain diligent patent prosecution, monitor potential infringers, and continually evaluate claims’ validity against evolving prior art.
References
- CNIPA Patent Database. Access and review of the full text of CN101679325.
- China Patent Law. For understanding patentability criteria applicable during Chinese examination.
- Pharmaceutical Patent Strategies. Industry best practices and landscape analysis reports.
- Patent Examination Guidelines (China). For insight into claim scope evaluation and patent validity standards.
- Market Reports. Chinese pharmaceutical industry reports highlighting key players and patent trends.
Note: For personalized legal advice or an in-depth patent drafting review, consult a qualified Chinese patent attorney or patent agent.
